Completion date	Site Number	
☐☐/☐☐☐/☐☐☐☐ (dd/mon/yyyy)	☐☐☐☐☐ Site Practitioner name _____	SMART-C

PRACTITIONER ACCEPTABILITY QUESTIONNAIRE – PRE-SCREENING

INSTRUCTIONS

One questionnaire is to be completed **each by the site Principal Investigator and the primary Research Nurse** prior to the commencement of screening.

SECTION 1: YOUR DETAILS

1. Practitioner type:
- ☐ Hepatologist
- ☐ Infectious Diseases
- ☐ General Practitioner
- ☐ Other Medical Doctor, please specify _____
- ☐ Study Nurse/Study Coordinator

SECTION 2: HCV TREATMENT EXPERIENCE

2. Previous experience with treating HCV patients:
- ☐ < 2 years
- ☐ 2-4 years
- ☐ > 4 years

3. Previous experience with IFN free DAA treatment:
- ☐ < 1 years
- ☐ 1 - 2 years
- ☐ > 2 years

SECTION 3: CURRENT PRACTICE

4. For a <u>treatment naïve, non-cirrhotic patient without a history of recent injecting drug use</u>, please indicate when and who would typically see the patient in clinic during short course HCV DAA treatment.

Note: if a clinic visit is not routine for your practice, please tick the "No clinic visit" box for the visit type.

Select all that apply.

Visit	Screening	Baseline	Week 4	Week 8 (12-week regimens only)	EOT	SVR12	SVR24
Week	*-*	*0*	*4*	*-*	*8 or 12*	*20 or 24*	*32 or 36*
Nurse	☐	☐	☐	☐	☐	☐	☐
Doctor	☐	☐	☐	☐	☐	☐	☐
Other practitioner	☐	☐	☐	☐	☐	☐	☐
No clinic visit	☐	☐	☐	☐	☐	☐	☐

Completion date	Site Number	
☐☐/☐☐☐/☐☐☐☐	☐☐☐☐☐	**SMART-C**
(dd/mon/yyyy)	Site Practitioner name	
	_____	

PRACTITIONER ACCEPTABILITY QUESTIONNAIRE – PRE-SCREENING

SECTION 4: SIMPLIFIED TREATMENT MONITORING EXPECTATIONS

5. Please rate the protocol simplified monitoring strategy based on the following: *Do you expect…*

	Lower in the simplified group than in the standard one	Equivalent in both treatment monitoring strategies	Higher in the simplified group than in the standard one
treatment adherence will be	☐	☐	☐
SVR12 will be	☐	☐	☐
adverse Events reported rate will be	☐	☐	☐
lost to follow up rates will be	☐	☐	☐
treatment discontinuation rates will be	☐	☐	☐

6. Which monitoring strategy do you prefer for this study's patient population?
    ☐ Standard monitoring
    ☐ Simplified monitoring
    ☐ Other, specify _____